Veale D, Kerr N, Gibson G J, Kelly P J, Harris A L
Department of Respiratory Medicine, Freeman Hospital, Newcastle upon Tyne, UK.
Br J Cancer. 1993 Jul;68(1):162-5. doi: 10.1038/bjc.1993.306.
Increased expression of epidermal growth factor receptor (EGFr) has been reported in non small cell lung cancers (NSCLC) when compared to normal lung. We have examined post-operative survival in 19 surgically treated patients with NSCLC who had full characterisation of EGFr on primary tumour membrane preparations from resection specimens. There were ten squamous, seven adeno and two large cell carcinomas. The median concentration of high affinity sites was 31 fmol per mg of protein (4-1532) and the median dissociation constant (Kd) of these high affinity sites was 2.3 x 10(-10) per mol (1.2-30 x 10(-10)). Seven patients survived over 5 years. Twelve patients died between 8.5 and 55 months from the time of surgery. When > 5 year survivors were compared to non-survivors there was no difference as regards tumour size or stage, or as regards age or sex. The survivors had a median concentration of high affinity EGFr sites of 16.1 fmol mg-1 protein compared to a median concentration of 68.6 fmol mg-1 protein in the non-survivors (P = 0.01 Wilcoxon test). No long term survivor had > 35 fmol mg-1 protein of receptor. Thus EGFr quantitation may give independent prognostic information in NSCLC and help to select patients for adjuvant therapy after surgery. These results need confirmation in a larger prospective study.
与正常肺组织相比，非小细胞肺癌（NSCLC）中表皮生长因子受体（EGFr）的表达有所增加。我们检测了19例接受手术治疗的NSCLC患者的术后生存率，这些患者的切除标本中原发性肿瘤膜制剂上的EGFr具有完整特征。其中有10例鳞状细胞癌、7例腺癌和2例大细胞癌。高亲和力位点的中位浓度为每毫克蛋白质31飞摩尔（4 - 1532），这些高亲和力位点的中位解离常数（Kd）为每摩尔2.3×10⁻¹⁰（1.2 - 30×10⁻¹⁰）。7例患者存活超过5年。12例患者在手术后8.5至55个月之间死亡。当将5年以上的幸存者与非幸存者进行比较时，在肿瘤大小或分期、年龄或性别方面没有差异。幸存者中高亲和力EGFr位点的中位浓度为16.1飞摩尔/毫克蛋白质，而非幸存者中的中位浓度为68.6飞摩尔/毫克蛋白质（Wilcoxon检验，P = 0.01）。没有长期幸存者的受体蛋白含量超过35飞摩尔/毫克。因此，EGFr定量可能为NSCLC提供独立的预后信息，并有助于选择术后辅助治疗的患者。这些结果需要在更大规模的前瞻性研究中得到证实。
